Spero Therapeutics (NASDAQ:SPRO) announced its earnings results on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.49, Fidelity Earnings reports. Spero Therapeutics had a negative net margin of 342.70% and a negative return on equity of 35.26%. The business had revenue of $7.72 million during the quarter, compared to analyst estimates of $1.25 million.
SPRO stock opened at $12.69 on Friday. Spero Therapeutics has a one year low of $5.52 and a one year high of $18.23.
Several equities research analysts have issued reports on SPRO shares. Zacks Investment Research lowered shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, January 12th. Oppenheimer set a $30.00 target price on shares of Spero Therapeutics and gave the company a “buy” rating in a research report on Sunday, January 13th. Cantor Fitzgerald started coverage on shares of Spero Therapeutics in a research report on Monday, February 4th. They set a “buy” rating and a $27.00 target price for the company. Finally, TheStreet lowered shares of Spero Therapeutics from a “c-” rating to a “d” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. Spero Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $21.80.
ILLEGAL ACTIVITY WARNING: This article was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://dakotafinancialnews.com/2019/05/11/spero-therapeutics-spro-announces-quarterly-earnings-results.html.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.
Featured Article: Short Selling Stocks and Day Traders
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.